EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

A novel Ondansetron extended release injectable suspension (OERIS): evaluation of Safety, tolerability and pharmacokinetics in a phase I trial

Veerendra Kumar Panuganti iD, Chandrasekhar Varma Alluri, Venkata Ramalingayya Grandhi, Javeed Mohammad, Sanyasirao K S S V V, Mamatha Reddy Dundigalla, Pavan Kumar Madala

Cancer Chemotherapy and Pharmacology · 2025

DOI: 10.1007/s00280-025-04820-6 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Cancer Chemotherapy and Pharmacology, 2025. Verfasst von Veerendra Kumar Panuganti und 6 weiteren Autor:innen. Beteiligte Einrichtung: Shilpa Medicare Limited, Plot No 79, Road No.15, IDA, Mallapur, Nacharam, Hyderabad, 500076, Telangana, India. veerendrap.frd@shilpamedicare.com. Hauptthemen laut MEDLINE: Ondansetron, Antiemetics, Vomiting, Nausea. Die Arbeit nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Chemotherapy-Induced Nausea and Vomiting (CINV) has a significant negative impact on cancer chemotherapy and patients' quality of life (QOL). Purpose of this study is to establish the safety, tolerability and pharmacokinetics of novel Ondansetron Extended Release Injectable Suspension (OERIS) through preclinical and clinical studies. Antiemetic medications, especially 5-HT3 antagonists like ondansetron, granisetron, neurokinin1 antagonists (aprepitant, fosaprepitant etc.) have proven to be effective in the prevention and control of CINV. However, ondansetron is currently available as oral tablet/solutions or IM/IV formulations requiring multiple dosing 3-5 days during chemotherapy. Novel OERIS formulation is developed with an aim to provide a single dose treatment strategy for an effective prophylaxis of acute and delayed phases of CINV. METHODS: Preclinical studies in rats and dogs viz. maximum tolerated dose, sub-acute toxicity and pharmacokinetic studies were conducted to support safety and pharmacokinetic assessments and before initiating human studies. Subsequently, a Phase I study was conducted in 24 healthy male human volunteers to evaluate safety, tolerability and pharmacokinetics. Study involves 4 arms with 6 subjects in each arm administered with either one of the 3 doses of OERIS (35, 70 and 100 mg, IM) or reference (24 mg, IV in 3 divided doses). RESULTS: No Observed Adverse Effect Level (NOAEL) was found to be 150 mg/kg, i.m. in rats, which is approximately 160 times that of recommended ondansetron human dose (0.15 mg/kg, i.v.). Phase I study of OERIS demonstrated optimal PK exposures for efficacy up to 5-days within therapeutic window along with good safety (no QT prolongation and no hypokalemia) and tolerability (no injection site reactions) in healthy subjects at a dose of 100 mg. CONCLUSION: OERIS is a promising, convenient, safe anti-emetic therapy effective for acute and delayed phases (lasts for 5-days) of CINV in patients receiving chemotherapy with a single dose. TRIAL REGISTRATION: The trial is registered at Clinical Trial Registry of India (CTRI) with registration number: CTRI/2022/07/043886 (Registered on: 11/07/2022).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OndansetronAntiemeticsVomitingNauseaMaleHumansAnimalsRatsAdultDogsDelayed-Action PreparationsMiddle AgedMaximum Tolerated DoseSuspensionsYoung AdultRats, Sprague-DawleyFemaleAntineoplastic Agents

Stichwörter der Autor:innen

CINVExtended releaseHECMECMTDOndansetron

Substanzen

OndansetronAntiemeticsDelayed-Action PreparationsSuspensionsAntineoplastic Agents

Autor:innen und Institutionen

  • Shilpa Medicare Limited, Plot No 79, Road No.15, IDA, Mallapur, Nacharam, Hyderabad, 500076, Telangana, India. veerendrap.frd@shilpamedicare.com.
  • Shilpa Medicare Limited, Plot No 79, Road No.15, IDA, Mallapur, Nacharam, Hyderabad, 500076, Telangana, India.

ORCID-Profile: Veerendra Kumar Panuganti

Zitieren

APA

Panuganti, V. K., Alluri, C. V., Grandhi, V. R., Mohammad, J., K S S V V, S., Dundigalla, M. R., & Madala, P. K. (2025). A novel Ondansetron extended release injectable suspension (OERIS): evaluation of Safety, tolerability and pharmacokinetics in a phase I trial. Cancer Chemotherapy and Pharmacology. https://doi.org/10.1007/s00280-025-04820-6

Vancouver

Panuganti VK, Alluri CV, Grandhi VR, Mohammad J, K S S V V S, Dundigalla MR, et al. A novel Ondansetron extended release injectable suspension (OERIS): evaluation of Safety, tolerability and pharmacokinetics in a phase I trial. Cancer Chemotherapy and Pharmacology. 2025. doi:10.1007/s00280-025-04820-6

BibTeX
@article{Panuganti2025,
  author = {Panuganti, Veerendra Kumar and Alluri, Chandrasekhar Varma and Grandhi, Venkata Ramalingayya and Mohammad, Javeed and K S S V V, Sanyasirao and Dundigalla, Mamatha Reddy and Madala, Pavan Kumar},
  title = {A novel Ondansetron extended release injectable suspension (OERIS): evaluation of Safety, tolerability and pharmacokinetics in a phase I trial},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2025},
  doi = {10.1007/s00280-025-04820-6}
}
Kostenlos starten →